Ritholtz Wealth Management grew its stake in shares of Gilead Sciences, Inc. (NASDAQ:GILD - Free Report) by 16.1% during the 1st quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The firm owned 102,440 shares of the biopharmaceutical company's stock after purchasing an additional 14,212 shares during the period. Ritholtz Wealth Management's holdings in Gilead Sciences were worth $11,478,000 as of its most recent filing with the Securities and Exchange Commission.
Several other institutional investors have also recently made changes to their positions in the stock. Annis Gardner Whiting Capital Advisors LLC raised its holdings in shares of Gilead Sciences by 158.8% in the 4th quarter. Annis Gardner Whiting Capital Advisors LLC now owns 352 shares of the biopharmaceutical company's stock worth $33,000 after acquiring an additional 216 shares during the last quarter. Morton Brown Family Wealth LLC acquired a new stake in shares of Gilead Sciences in the 4th quarter worth about $35,000. Whipplewood Advisors LLC acquired a new stake in shares of Gilead Sciences in the 4th quarter worth about $35,000. Synergy Investment Management LLC acquired a new stake in shares of Gilead Sciences in the 4th quarter worth about $40,000. Finally, Lee Danner & Bass Inc. acquired a new stake in shares of Gilead Sciences in the 4th quarter worth about $41,000. Institutional investors and hedge funds own 83.67% of the company's stock.
Gilead Sciences Stock Performance
GILD traded down $2.07 on Friday, hitting $109.98. The company's stock had a trading volume of 8,148,740 shares, compared to its average volume of 7,744,306. The company's 50 day simple moving average is $105.67 and its 200-day simple moving average is $102.26. The firm has a market cap of $136.81 billion, a P/E ratio of 297.24, a price-to-earnings-growth ratio of 0.71 and a beta of 0.29. Gilead Sciences, Inc. has a 12 month low of $62.69 and a 12 month high of $119.96. The company has a quick ratio of 1.20, a current ratio of 1.50 and a debt-to-equity ratio of 1.24.
Gilead Sciences (NASDAQ:GILD - Get Free Report) last released its quarterly earnings data on Thursday, April 24th. The biopharmaceutical company reported $1.81 EPS for the quarter, topping the consensus estimate of $1.77 by $0.04. The company had revenue of $6.67 billion during the quarter, compared to the consensus estimate of $6.77 billion. Gilead Sciences had a net margin of 1.67% and a return on equity of 31.63%. Gilead Sciences's revenue for the quarter was down .3% on a year-over-year basis. During the same period last year, the firm earned ($1.32) EPS. Analysts forecast that Gilead Sciences, Inc. will post 7.95 EPS for the current year.
Gilead Sciences Announces Dividend
The company also recently announced a quarterly dividend, which will be paid on Friday, June 27th. Shareholders of record on Friday, June 13th will be paid a $0.79 dividend. This represents a $3.16 annualized dividend and a yield of 2.87%. The ex-dividend date of this dividend is Friday, June 13th. Gilead Sciences's dividend payout ratio is presently 66.53%.
Analyst Upgrades and Downgrades
A number of equities research analysts recently weighed in on GILD shares. Cantor Fitzgerald started coverage on shares of Gilead Sciences in a report on Tuesday, April 22nd. They issued an "overweight" rating and a $125.00 target price on the stock. Deutsche Bank Aktiengesellschaft upgraded shares of Gilead Sciences from a "hold" rating to a "buy" rating and upped their target price for the stock from $80.00 to $120.00 in a report on Tuesday, February 18th. Morgan Stanley upped their target price on shares of Gilead Sciences from $130.00 to $135.00 and gave the stock an "overweight" rating in a report on Friday, April 25th. Oppenheimer decreased their price objective on shares of Gilead Sciences from $132.00 to $125.00 and set an "outperform" rating for the company in a research note on Friday, April 25th. Finally, Needham & Company LLC reiterated a "hold" rating on shares of Gilead Sciences in a research note on Wednesday, May 21st. Nine investment analysts have rated the stock with a hold rating, fifteen have assigned a buy rating and three have given a strong buy rating to the company's stock. Based on data from MarketBeat, the stock presently has a consensus rating of "Moderate Buy" and an average price target of $110.55.
Get Our Latest Report on Gilead Sciences
Insiders Place Their Bets
In other news, CEO Daniel Patrick O'day sold 10,000 shares of the firm's stock in a transaction on Friday, May 30th. The shares were sold at an average price of $110.42, for a total transaction of $1,104,200.00. Following the sale, the chief executive officer now owns 620,268 shares in the company, valued at approximately $68,489,992.56. This trade represents a 1.59% decrease in their position. The transaction was disclosed in a filing with the SEC, which can be accessed through this link. Also, CFO Andrew D. Dickinson sold 2,500 shares of the firm's stock in a transaction on Tuesday, April 15th. The shares were sold at an average price of $106.40, for a total transaction of $266,000.00. Following the sale, the chief financial officer now owns 168,174 shares in the company, valued at approximately $17,893,713.60. This trade represents a 1.46% decrease in their position. The disclosure for this sale can be found here. Insiders have sold 43,000 shares of company stock worth $4,630,310 in the last three months. 0.27% of the stock is currently owned by corporate insiders.
About Gilead Sciences
(
Free Report)
Gilead Sciences, Inc, a biopharmaceutical company, discovers, develops, and commercializes medicines in the areas of unmet medical need in the United States, Europe, and internationally. The company provides Biktarvy, Genvoya, Descovy, Odefsey, Truvada, Complera/ Eviplera, Stribild, Sunlencs, and Atripla products for the treatment of HIV/AIDS; Veklury, an injection for intravenous use, for the treatment of COVID-19; and Epclusa, Harvoni, Vemlidy, and Viread for the treatment of viral hepatitis.
Featured Stories
Before you consider Gilead Sciences, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Gilead Sciences wasn't on the list.
While Gilead Sciences currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Nuclear energy stocks are roaring. It's the hottest energy sector of the year. Cameco Corp, Paladin Energy, and BWX Technologies were all up more than 40% in 2024. The biggest market moves could still be ahead of us, and there are seven nuclear energy stocks that could rise much higher in the next several months. To unlock these tickers, enter your email address below.
Get This Free Report
